Alkermes
852 Winter Street
Waltham
Massachusetts
02451
United States
Tel: 781-609-6000
Website: http://www.alkermes.com/
Email: mediainfo@alkermes.com
About Alkermes
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com .
Key Executives:
Richard F. Pops- Chairman and Chief Executive Officer
Shane Cooke- President
Kathryn L. Biberstein- Executive Vice President, Chief Compliance Officer and Chief Administrative Officer, and Secretary Alkermes plc
Iain Brown- Senior Vice President, Finance and Chief Accounting Officer
Madeline D. Coffin- Senior Vice President, Human Resources
Elliot W. Ehrich, M.D.- Executive Vice President, Research and Development
James M. Frates- Senior Vice President, Chief Financial Officer
David J Gaffin- Senior Vice President, Chief Legal Officer
Georgianna Harris, Ph.D.- Senior Vice President, Regulatory Affairs
Craig Hopkinson, M.D.- Chief Medical Officer, and Senior Vice President of Clinical Development and Medical Affairs
Blair C. Jackson- Senior Vice President, Business Development
Michael J. Landine- Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.- Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman- Vice President, Government Affairs and Policy
Declan O’Connor- Senior Vice President, Operations
Phil Shanahan, Ph.D.- Vice President, Quality Operations
Mark P. Stejbach- Senior Vice President, Chief Commercial Officer
Locations
Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
Waltham, Massachusetts
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Athlone, Ireland
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000
Gainesville, Georgia
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100
Wilmington, Ohio
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
676 articles about Alkermes
-
Alkermes' Corporate Presentation to be Webcast at the Lazard Capital Markets Healthcare Conference
11/11/2009
-
Alkermes Reports Second Quarter Fiscal 2010 Financial Results
11/6/2009
-
Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse Healthcare Conference
11/5/2009
-
Alkermes to Host Conference Call to Discuss Financial Results for Second Quarter of Fiscal 2010
10/30/2009
-
Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation
10/27/2009
-
Alkermes Announces Positive Results From Two Clinical Trials of ALKS 33
10/13/2009
-
Alkermes Announces Amylin Pharmaceuticals, Inc. and Eli Lilly and Company Will Present More than 20 Studies for Exenatide at EASD 2009
9/24/2009
-
Alkermes Chairman Richard Pops to Resume Role of CEO
9/11/2009
-
Alkermes' Corporate Presentation to be Webcast at the BioCentury NewsMakers Conference
9/10/2009
-
Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Healthcare Conference
9/9/2009
-
Alkermes' Corporate Presentation to be Webcast at the Thomas Weisel Partners Annual Healthcare Conference
9/3/2009
-
Alkermes Says Johnson & Johnson Will Not Pursue Further Development of Four-week Risperidone
8/27/2009
-
Alkermes Reports First Quarter Fiscal 2010 Financial Results
8/7/2009
-
Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2010
7/31/2009
-
Alkermes' Corporate Presentation to be Webcast at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
7/30/2009
-
Alkermes's Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) in Head-to-Head DURATION-3 Study
7/21/2009
-
FDA will Review Amylin Pharmaceuticals, Inc., Eli Lilly and Company, and Alkermes' Exenatide Application
7/8/2009
-
Alkermes: New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
7/8/2009
-
Alkermes' Corporate Presentation to be Webcast at the Jefferies & Company 3rd Annual Healthcare Conference
6/11/2009
-
Alkermes' Corporate Presentation to be Webcast at Two Upcoming Investor Conferences
6/3/2009